Raymond Penn hopes to develop drugs that manage asthma better and avoid some of the safety and efficacy concerns seen with current therapies.

The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments ...

New study shows that targeting an oft-drugged family of cell membrane receptors with biased modulators can expand potential ...

Roche may have been exploring ways to shuttle drugs to the brain for well over a decade, but that’s not stopping the pharma ...

Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the ...

Specifically, this is a result of our team driving increases in 2 key areas. Firstly ... owned monoclonal antibody antagonist ...

Most current approaches rely on adding nuclear localization signal (NLS) motifs to the ends of Cas9 to facilitate nuclear entry. However, this method is inefficient, and much of the Cas9 that is ...

POTOMAC, MARYLAND / ACCESS Newswire / November 3, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop i ...

Dr. Mary Maluccio discusses the promising next steps for 212Pb-DOTAMTATE in treating GEP-NETs, including a pivotal phase 3 ...

POTOMAC, MARYLAND / ACCESS Newswire / November 3, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") , a clinical-stage biotechnology company leveraging AI to develop innovative ...

PHOENIX — The oral medication resmetirom significantly improved liver stiffness and reduced portal hypertension in metabolic ...

ADAS-Cog13 difference -12.78 (P 77.4 Weeks (17.8 Months) 'time saved' with oral blarcamesine compared to ADNI Restoring ...